Scholarlink

Purpose <p>The purpose of this study is to examine the efficacy of 500&#xa0;mg levofloxacin and 3&#xa0;g fosfomycin given as single-dose prophylactic antibiotics one hour before urodynamic studies (UDS) to prevent urinary tract infections (UTIs).</p> Methods <p>This single-blinded, randomized clinical trial included 126 patients who underwent UDS between December 2022 and March 2024 at two urology centers in Jakarta. The patients, aged 18 years and older, were randomized equally into two groups receiving either 500&#xa0;mg levofloxacin or 3&#xa0;g fosfomycin prior to UDS. The primary indications for UDS included lower urinary tract symptoms (LUTS) (54.8%), overactive bladder (OAB) (32.8%), underactive bladder (8.9%), and stress urinary incontinence (3.5%). Three days post-UDS, patients were followed up with urinalysis and clinical assessment for UTI symptoms.</p> Results <p>Among the 126 patients, UTI was diagnosed in 26 cases (20.9%), with 14 cases (22.2%) in the levofloxacin group and 12 cases (19%) in the fosfomycin group, showing no significant difference (<i>p</i> = 0.660). Symptomatic UTIs occurred in 6 patients (4.8%) in the levofloxacin group and 7 patients (5.6%) in the fosfomycin group. E. coli was the most commonly detected bacterium in urine cultures.</p> Conclusion <p>In our center, there was no significant difference in the clinical outcome between the administration of 3&#xa0;g fosfomycin and 500&#xa0;mg levofloxacin as single-dose prophylactic antibiotics prior to UDS. Given the rising antibiotic resistance, fosfomycin may be considered an alternative. Further multicenter and multinational studies are warranted, as bacterial profiles and antibiotic resistance patterns may vary across different regions and healthcare systems.</p> Trial registration <p>NCT06017479.</p> Study Registration Date <p>2023-08-24.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of the effectiveness of single-dose levofloxacin with single-dose fosfomycin pre-urodynamic study related to the incidence of urinary tract infection: a randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月14日

查看全文
  • Harrina Erlianti Rahardjo,
  • Fina Widia,
  • Cindy Wijaya,
  • Kevin Leonardo,
  • Alfred Tanjung,
  • Muhammad Hanif Arfiananda,
  • Fatimah Nuwwaaridya Fitriani,
  • Rahmat Aidil Fajar Siregar,
  • Andika Afriansyah

摘要

Purpose

The purpose of this study is to examine the efficacy of 500 mg levofloxacin and 3 g fosfomycin given as single-dose prophylactic antibiotics one hour before urodynamic studies (UDS) to prevent urinary tract infections (UTIs).

Methods

This single-blinded, randomized clinical trial included 126 patients who underwent UDS between December 2022 and March 2024 at two urology centers in Jakarta. The patients, aged 18 years and older, were randomized equally into two groups receiving either 500 mg levofloxacin or 3 g fosfomycin prior to UDS. The primary indications for UDS included lower urinary tract symptoms (LUTS) (54.8%), overactive bladder (OAB) (32.8%), underactive bladder (8.9%), and stress urinary incontinence (3.5%). Three days post-UDS, patients were followed up with urinalysis and clinical assessment for UTI symptoms.

Results

Among the 126 patients, UTI was diagnosed in 26 cases (20.9%), with 14 cases (22.2%) in the levofloxacin group and 12 cases (19%) in the fosfomycin group, showing no significant difference (p = 0.660). Symptomatic UTIs occurred in 6 patients (4.8%) in the levofloxacin group and 7 patients (5.6%) in the fosfomycin group. E. coli was the most commonly detected bacterium in urine cultures.

Conclusion

In our center, there was no significant difference in the clinical outcome between the administration of 3 g fosfomycin and 500 mg levofloxacin as single-dose prophylactic antibiotics prior to UDS. Given the rising antibiotic resistance, fosfomycin may be considered an alternative. Further multicenter and multinational studies are warranted, as bacterial profiles and antibiotic resistance patterns may vary across different regions and healthcare systems.

Trial registration

NCT06017479.

Study Registration Date

2023-08-24.